Trial Outcomes & Findings for A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT NCT03734016)

NCT ID: NCT03734016

Last Updated: 2025-03-30

Results Overview

ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) per investigator assessment. Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 652 participants
• Primary outcome timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
• Results posted on: 2025-03-30

Participant Flow

This study was conducted at 113 study centers in 15 countries (Australia, Belgium, China, the Czech Republic, France, Germany, Italy, the Netherlands, New Zealand, Poland, Spain, Sweden, Turkey, the United Kingdom, and the United States).

Participants were randomly assigned to one of two treatment groups. Randomization was stratified according to age (< 65 versus ≥ 65 years), geographic region (China vs non-China), refractory status (yes or no), and chromosome 17p deletion or TP53 mutation status (present or absent).

Participant milestones

Measure	Zanubrutinib Participants received 160 milligrams (mg) zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Overall Study STARTED	327	325
Overall Study Received Study Drug	324	324
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	327	325

Reasons for withdrawal

Measure	Zanubrutinib Participants received 160 milligrams (mg) zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Overall Study Sponsor Ended Study	225	200
Overall Study Death	69	83
Overall Study Withdrawal by Subject	21	27
Overall Study Physician Decision	1	12
Overall Study Lost to Follow-up	6	2
Overall Study Miscellaneous	5	1

Baseline Characteristics

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Baseline characteristics by cohort

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Total n=652 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants
Age, Categorical Between 18 and 65 years	126 Participants n=93 Participants	125 Participants n=4 Participants	251 Participants n=27 Participants
Age, Categorical >=65 years	201 Participants n=93 Participants	200 Participants n=4 Participants	401 Participants n=27 Participants
Age, Continuous	67.0 years n=93 Participants	68.0 years n=4 Participants	67.0 years n=27 Participants
Sex: Female, Male Female	114 Participants n=93 Participants	93 Participants n=4 Participants	207 Participants n=27 Participants
Sex: Female, Male Male	213 Participants n=93 Participants	232 Participants n=4 Participants	445 Participants n=27 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	7 Participants n=93 Participants	13 Participants n=4 Participants	20 Participants n=27 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	309 Participants n=93 Participants	298 Participants n=4 Participants	607 Participants n=27 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	11 Participants n=93 Participants	14 Participants n=4 Participants	25 Participants n=27 Participants
Race/Ethnicity, Customized Asian	47 Participants n=93 Participants	44 Participants n=4 Participants	91 Participants n=27 Participants
Race/Ethnicity, Customized Black or African American	4 Participants n=93 Participants	2 Participants n=4 Participants	6 Participants n=27 Participants
Race/Ethnicity, Customized Native Hawaiian or Pacific Islander	3 Participants n=93 Participants	0 Participants n=4 Participants	3 Participants n=27 Participants
Race/Ethnicity, Customized White	261 Participants n=93 Participants	265 Participants n=4 Participants	526 Participants n=27 Participants
Race/Ethnicity, Customized Other	2 Participants n=93 Participants	2 Participants n=4 Participants	4 Participants n=27 Participants
Race/Ethnicity, Customized Multiple	1 Participants n=93 Participants	0 Participants n=4 Participants	1 Participants n=27 Participants
Race/Ethnicity, Customized Unknown/Not Reported	9 Participants n=93 Participants	12 Participants n=4 Participants	21 Participants n=27 Participants
Geographic Region Asia	49 Participants n=93 Participants	45 Participants n=4 Participants	94 Participants n=27 Participants
Geographic Region Australia/New Zealand	28 Participants n=93 Participants	30 Participants n=4 Participants	58 Participants n=27 Participants
Geographic Region Europe	198 Participants n=93 Participants	191 Participants n=4 Participants	389 Participants n=27 Participants
Geographic Region North America	52 Participants n=93 Participants	59 Participants n=4 Participants	111 Participants n=27 Participants
Chromosome 17p Deletion (del[17p]) and TP53 Mutation Status Del(17p) and/or TP53 mutation	75 Participants n=93 Participants	75 Participants n=4 Participants	150 Participants n=27 Participants
Chromosome 17p Deletion (del[17p]) and TP53 Mutation Status Neither Del(17p) nor TP53 mutation	251 Participants n=93 Participants	250 Participants n=4 Participants	501 Participants n=27 Participants
Chromosome 17p Deletion (del[17p]) and TP53 Mutation Status Missing	1 Participants n=93 Participants	0 Participants n=4 Participants	1 Participants n=27 Participants

PRIMARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: Intent To Treat (ITT) Analysis Set

ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) per investigator assessment.

Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Overall Response Rate (ORR) Assessed by the Investigator	83.5 percentage of participants Interval 79.0 to 87.3	74.2 percentage of participants Interval 69.0 to 78.8

PRIMARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: ITT Analysis Set

ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) assessed by a blinded independent review committee. Overall response was assessed by the IRC for the purpose of regulatory filing with the Food and Drug Administration (FDA).

Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
ORR Assessed by the Independent Review Committee (IRC)	86.2 percentage of participants Interval 82.0 to 89.8	75.7 percentage of participants Interval 70.7 to 80.3

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: ITT Analysis Set

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Progression-free Survival (PFS) Assessed by the Investigator	NA months Interval 34.3 to Insufficient number of participants with events to estimate median and upper 95% confidence limit.	34.2 months Interval 33.3 to Insufficient number of participants with events to estimate upper 95% confidence limit.

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: Intent To Treat Analysis Set

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Progression-free Survival Assessed by the Independent Review Committee	NA months Interval 34.3 to Insufficient number of participants with events to estimate median and upper 95% confidence limit.	35.0 months Interval 33.2 to 44.3

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: The Safety Analysis Set includes all participants who received any dose of study drug.

Participants were considered as having an atrial fibrillation/flutter event if they had a treatment-emergent AE of either "atrial fibrillation" or "atrial flutter".

Outcome measures

Measure	Zanubrutinib n=324 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=324 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Percentage of Participants With Atrial Fibrillation or Atrial Flutter	5.2 percentage of participants Interval 3.1 to 8.3	13.3 percentage of participants Interval 9.8 to 17.5

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: Participants in the ITT Analysis Set with an objective response assessed by the IRC

DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by independent central review. Median DOR was estimated using the Kaplan-Meier method.

Outcome measures

Measure	Zanubrutinib n=282 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=246 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Duration of Response Assessed by the Independent Review Committee	NA months Interval 31.3 to Insufficient number of participants with events to estimate median and upper 95% confidence limit.	33.9 months Interval 32.2 to 41.4

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: Participants in the ITT Analysis Set with an objective response as assessed by the investigator

DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by investigator assessment. Median DOR was estimated using the Kaplan-Meier method.

Outcome measures

Measure	Zanubrutinib n=273 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=241 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Duration of Response (DOR) Assessed by the Investigator	NA months Interval 31.3 to Insufficient number of participants with events to estimate median and upper 95% confidence limit.	33.9 months Interval 33.9 to Insufficient number of participants with events to estimate upper 95% confidence limit.

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: ITT Analysis Set

Time to treatment failure is defined as the time from randomization to discontinuation of study drug due to any reason. Median time to treatment failure was estimated by the Kaplan-Meier method.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Time to Treatment Failure	NA months Insufficient number of participants with events to estimate median and 95% confidence interval.	NA months Interval 34.4 to Insufficient number of participants with events to estimate median and upper 95% confidence limit.

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: ITT Analysis Set

The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or a complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis assessed by the blinded IRC.

Disease response was assessed per iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and per Lugano classification for participants with SLL.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee	91.7 percentage of participants Interval 88.2 to 94.5	83.1 percentage of participants Interval 78.5 to 87.0

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: ITT Analysis Set

The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis as assessed by the investigator.

Disease response was assessed according to the iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and in accordance with Lugano classification for participants with SLL.

Partial response with lymphocytosis: blood lymphocytes decreased < 50% or increased from baseline, and otherwise meeting criteria for PR.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Investigator	89.9 percentage of participants Interval 86.1 to 93.0	82.5 percentage of participants Interval 77.9 to 86.4

SECONDARY outcome

Timeframe: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Population: ITT Analysis Set

Overall survival is defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

Outcome measures

Measure	Zanubrutinib n=327 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=325 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Overall Survival (OS)	NA months Insufficient number of participants with events to estimate median and 95% confidence interval.	NA months Insufficient number of participants with events to estimate median and 95% confidence interval.

SECONDARY outcome

Timeframe: Baseline and Weeks 24 and 48

Population: Participants in the ITT Analysis Set who completed the EORTC QLQ-C30 at Baseline

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

Outcome measures

Measure	Zanubrutinib n=315 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=313 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores GHS/QoL Scale at Week 24	8.18 score on a scale Interval 6.25 to 10.12	5.18 score on a scale Interval 3.2 to 7.17
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores GHS/QoL Scale at Week 48	7.28 score on a scale Interval 5.41 to 9.15	5.93 score on a scale Interval 3.97 to 7.89
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores Physical Functioning Scale at Week 24	6.55 score on a scale Interval 4.96 to 8.15	4.73 score on a scale Interval 3.08 to 6.38
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores Physical Functioning Scale at Week 48	5.46 score on a scale Interval 3.87 to 7.04	4.31 score on a scale Interval 2.65 to 5.97
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores Role Functioning Scale at Week 24	6.95 score on a scale Interval 4.85 to 9.06	6.32 score on a scale Interval 4.14 to 8.5
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores Role Functioning Scale at Week 48	6.81 score on a scale Interval 4.61 to 9.02	5.01 score on a scale Interval 2.69 to 7.33

SECONDARY outcome

Timeframe: Baseline and Weeks 24 and 48

Population: Participants in the ITT Analysis Set who completed the EORTC QLQ-C30 at Baseline

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores in symptom scales indicate better quality of life.

Outcome measures

Measure	Zanubrutinib n=315 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=313 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Fatigue Symptom Scale at Week 48	-11.13 score on a scale Interval -13.19 to -9.08	-10.78 score on a scale Interval -12.93 to -8.63
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Nausea and Vomiting Symptom Scale at Week 24	-1.21 score on a scale Interval -2.03 to -0.38	-0.92 score on a scale Interval -1.77 to -0.07
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Fatigue Symptom Scale at Week 24	-12.54 score on a scale Interval -14.47 to -10.6	-10.63 score on a scale Interval -12.63 to -8.62
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Nausea and Vomiting Symptom Scale at Week 48	-0.92 score on a scale Interval -1.94 to 0.1	-0.40 score on a scale Interval -1.47 to 0.66
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Pain Symptom Scale at Week 24	-5.06 score on a scale Interval -7.21 to -2.91	-3.63 score on a scale Interval -5.85 to -1.42
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Pain Symptom Scale at Week 48	-5.18 score on a scale Interval -7.38 to -2.97	-2.75 score on a scale Interval -5.06 to -0.44
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Diarrhoea Symptom Scale at Week 24	-2.11 score on a scale Interval -3.8 to -0.42	-0.52 score on a scale Interval -2.27 to 1.22
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea Diarrhoea Symptom Scale at Week 48	-3.23 score on a scale Interval -4.79 to -1.66	-1.38 score on a scale Interval -3.03 to 0.27

SECONDARY outcome

Timeframe: Baseline and Weeks 24 and 48

Population: Participants in the ITT Analysis Set who completed the EQ-5D-5L VAS at Baseline; participants with available data at baseline and the relevant post-baseline visit are included in the analysis at each time point.

The EQ-5D-5L VAS measures a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Outcome measures

Measure	Zanubrutinib n=315 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=315 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Change From Baseline in European Quality of Life 5-dimensions 5-levels Health Questionnaire (EQ-5D-5L) Visual Analog Scale (VAS) Week 24	7.92 score on a scale Standard Deviation 18.245	3.44 score on a scale Standard Deviation 16.972
Change From Baseline in European Quality of Life 5-dimensions 5-levels Health Questionnaire (EQ-5D-5L) Visual Analog Scale (VAS) Week 48	7.75 score on a scale Standard Deviation 18.806	3.92 score on a scale Standard Deviation 16.778

SECONDARY outcome

Timeframe: From first dose of study drug up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm.

Population: The Safety Analysis Set includes all participants who received any dose of study drug.

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not.

A serious adverse event (SAE) is any untoward medical occurrence that, at any dose:

• Resulted in death
• Was life-threatening
• Required hospitalization or prolongation of existing hospitalization
• Resulted in disability/incapacity
• Resulted in a congenital anomaly/birth defect
• Was considered a significant medical AE by the investigator based on medical judgment

Outcome measures

Measure	Zanubrutinib n=324 Participants Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=324 Participants Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Number of Participants With Treatment-emergent Adverse Events (TEAE) Any TEAE	322 Participants	323 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE) Serious adverse events	172 Participants	196 Participants

Adverse Events

Zanubrutinib

Serious events: 172 serious events

Other events: 310 other events

Deaths: 69 deaths

Ibrutinib

Serious events: 196 serious events

Other events: 314 other events

Deaths: 83 deaths

Serious adverse events

Measure	Zanubrutinib n=324 participants at risk Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=324 participants at risk Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Infections and infestations Pneumonia klebsiella	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia legionella	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia parainfluenzae viral	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia influenzal	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Central nervous system haemorrhage	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia	7.4% 24/324 • Number of events 39 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	10.2% 33/324 • Number of events 47 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia bacterial	0.62% 2/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia cryptococcal	0.31% 1/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia fungal	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Anaemia	1.5% 5/324 • Number of events 8 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	1.2% 4/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Blood loss anaemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Febrile neutropenia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Haemolytic anaemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Hypoglobulinaemia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Immune thrombocytopenia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Lymphadenitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Lymphadenopathy	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Lymphocytosis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Neutropenia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Splenic haematoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Splenic haemorrhage	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Splenic infarction	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Thrombocytopenia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Acute coronary syndrome	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Acute myocardial infarction	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Angina pectoris	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Angina unstable	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Atrial fibrillation	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Atrial flutter	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Atrial tachycardia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Atrioventricular block second degree	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Cardiac arrest	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Cardiac failure	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Cardiac failure acute	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Cardiac failure chronic	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Cardiac failure congestive	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Coronary artery disease	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Dilated cardiomyopathy	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Myocardial infarction	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Myocardial ischaemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Right ventricular failure	0.31% 1/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Sinus bradycardia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Supraventricular tachycardia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Ventricular arrhythmia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Ventricular fibrillation	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Congenital, familial and genetic disorders Bronchogenic cyst	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Ear and labyrinth disorders Tinnitus	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Ear and labyrinth disorders Vertigo	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Eye disorders Cataract	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Eye disorders Cataract nuclear	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Eye disorders Dacryostenosis acquired	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Eye disorders Keratitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Eye disorders Optic ischaemic neuropathy	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Eye disorders Periorbital oedema	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Abdominal pain	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Chronic gastritis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Colitis	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Constipation	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Crohn's disease	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Diarrhoea	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Duodenal ulcer	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Enterocolitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Gastric ulcer perforation	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Inguinal hernia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Large intestine perforation	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Large intestine polyp	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Mesenteric panniculitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Noninfective sialoadenitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Obstructive pancreatitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Oesophageal food impaction	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Pancreatitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Small intestinal haemorrhage	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Strangulated umbilical hernia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Catheter site haematoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Chest pain	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Death	1.2% 4/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Drug withdrawal syndrome	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Fatigue	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Malaise	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Multiple organ dysfunction syndrome	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Non-cardiac chest pain	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Pyrexia	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	1.5% 5/324 • Number of events 6 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Hepatobiliary disorders Cholangitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Hepatobiliary disorders Cholecystitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Hepatobiliary disorders Cholecystitis acute	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Hepatobiliary disorders Cholelithiasis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Hepatobiliary disorders Hepatitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Hepatobiliary disorders Jaundice	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Acinetobacter bacteraemia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Anal abscess	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Appendicitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Arthritis bacterial	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Atypical pneumonia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Bacterial sepsis	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Bronchitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Bronchopulmonary aspergillosis	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations COVID-19	8.6% 28/324 • Number of events 35 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	6.2% 20/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations COVID-19 pneumonia	10.2% 33/324 • Number of events 44 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	6.8% 22/324 • Number of events 35 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Campylobacter gastroenteritis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Cellulitis	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Clostridium difficile colitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Dacryocystitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Encephalitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Encephalomyelitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Enterococcal sepsis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Epstein-Barr virus infection	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Erysipelas	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Escherichia bacteraemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Escherichia urinary tract infection	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Fungal abscess central nervous system	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Gastritis viral	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Gastroenteritis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Gastroenteritis viral	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Haematoma infection	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Helicobacter gastritis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Hepatitis B	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Herpes zoster	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Infection	0.31% 1/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Infective tenosynovitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Influenza	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Keratitis bacterial	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Keratitis fungal	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Large intestine infection	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Localised infection	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Lower respiratory tract infection	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Lower respiratory tract infection bacterial	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Lymphadenitis bacterial	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Mastoiditis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Meningitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Meningitis aseptic	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Orchitis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Otitis externa	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Otitis media acute	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Paronychia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumococcal sepsis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumocystis jirovecii pneumonia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia pneumococcal	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia pseudomonal	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia respiratory syncytial viral	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia viral	0.31% 1/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Post procedural infection	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pulmonary tuberculosis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Respiratory tract infection	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Sepsis	1.2% 4/324 • Number of events 6 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Septic shock	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Sinusitis	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Skin bacterial infection	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Soft tissue infection	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Sporotrichosis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Staphylococcal bacteraemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Staphylococcal sepsis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Streptococcal bacteraemia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Tick-borne viral encephalitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Upper respiratory tract infection	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Urinary tract infection	2.2% 7/324 • Number of events 8 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 13 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Urosepsis	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Wound infection	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Clavicle fracture	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Craniocerebral injury	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Fall	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Femur fracture	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Joint injury	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Limb injury	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Post procedural complication	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Road traffic accident	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Scapula fracture	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Spinal compression fracture	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Spinal fracture	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Splenic rupture	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Traumatic haematoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Traumatic liver injury	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Traumatic ulcer	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Wound dehiscence	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Alanine aminotransferase increased	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Aspartate aminotransferase increased	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Blood bilirubin increased	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Blood creatinine increased	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations False positive investigation result	0.31% 1/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Platelet count decreased	0.62% 2/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations White blood cell count decreased	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Cachexia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hyperglycaemia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Tumour lysis syndrome	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Water intoxication	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Back pain	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Bursitis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Chondrocalcinosis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Haemarthrosis	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Haematoma muscle	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Intervertebral disc compression	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Mobility decreased	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma gastric	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma of colon	0.31% 1/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Atypical fibroxanthoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.93% 3/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign lung neoplasm	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder transitional cell carcinoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Brain neoplasm	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Brain neoplasm malignant	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Choroid melanoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chromophobe renal cell carcinoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Clear cell renal cell carcinoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer metastatic	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal adenocarcinoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial adenocarcinoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrointestinal tract adenoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intraductal proliferative breast lesion	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal cancer recurrent	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lip squamous cell carcinoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lipoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Mantle cell lymphoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Mucoepidermoid carcinoma of salivary gland	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine carcinoma	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine carcinoma of the cervix	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oral haemangioma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	1.2% 4/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin squamous cell carcinoma metastatic	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer metastatic	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.93% 3/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Superficial spreading melanoma stage II	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thymoma malignant recurrent	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell cancer of the renal pelvis and ureter	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Carotid artery occlusion	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Cerebral haemorrhage	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Cerebral infarction	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Cerebrovascular accident	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Dysarthria	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Epilepsy	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Headache	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Ischaemic stroke	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Post herpetic neuralgia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Seizure	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Syncope	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Transient ischaemic attack	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Psychiatric disorders Delirium	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Psychiatric disorders Depression	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Psychiatric disorders Suicidal behaviour	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Acute kidney injury	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Bladder dysplasia	0.31% 1/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Chronic kidney disease	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Haematuria	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Nephrolithiasis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Renal failure	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Urinary retention	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Reproductive system and breast disorders Pelvic organ prolapse	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Reproductive system and breast disorders Uterine polyp	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Reproductive system and breast disorders Vulva cyst	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.62% 2/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Haemothorax	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Hydrothorax	0.31% 1/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Nasal obstruction	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Pulmonary necrosis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 4 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Aortic aneurysm rupture	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Haematoma	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Hypertension	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Hypertensive crisis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Orthostatic hypotension	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Peripheral arterial occlusive disease	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Peripheral artery stenosis	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Peripheral artery thrombosis	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Varicose vein	0.00% 0/324 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.31% 1/324 • Number of events 1 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.

Other adverse events

Measure	Zanubrutinib n=324 participants at risk Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.	Ibrutinib n=324 participants at risk Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.
Blood and lymphatic system disorders Anaemia	16.4% 53/324 • Number of events 82 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	17.3% 56/324 • Number of events 122 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Iron deficiency anaemia	1.9% 6/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 13 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Sinus bradycardia	2.5% 8/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 15 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Neutropenia	25.0% 81/324 • Number of events 195 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	22.5% 73/324 • Number of events 162 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Blood and lymphatic system disorders Thrombocytopenia	10.5% 34/324 • Number of events 90 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	10.8% 35/324 • Number of events 92 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Atrial fibrillation	6.8% 22/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	13.9% 45/324 • Number of events 69 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Cardiac failure	1.9% 6/324 • Number of events 7 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Cardiac disorders Palpitations	4.0% 13/324 • Number of events 19 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.3% 14/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Ear and labyrinth disorders Vertigo	3.4% 11/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	1.9% 6/324 • Number of events 6 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Eye disorders Cataract	5.6% 18/324 • Number of events 22 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Abdominal pain	6.2% 20/324 • Number of events 32 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	6.5% 21/324 • Number of events 23 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Abdominal pain upper	4.3% 14/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.2% 7/324 • Number of events 7 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Constipation	7.4% 24/324 • Number of events 30 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	8.3% 27/324 • Number of events 31 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Diarrhoea	18.8% 61/324 • Number of events 106 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	25.6% 83/324 • Number of events 158 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Dyspepsia	7.7% 25/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	7.1% 23/324 • Number of events 32 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Gastrooesophageal reflux disease	4.6% 15/324 • Number of events 22 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	5.2% 17/324 • Number of events 19 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Fatigue	11.1% 36/324 • Number of events 43 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	15.1% 49/324 • Number of events 57 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Mouth ulceration	1.5% 5/324 • Number of events 6 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Nausea	9.0% 29/324 • Number of events 47 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	9.9% 32/324 • Number of events 38 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Stomatitis	3.4% 11/324 • Number of events 17 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Toothache	3.1% 10/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	1.9% 6/324 • Number of events 9 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Gastrointestinal disorders Vomiting	6.8% 22/324 • Number of events 25 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	9.0% 29/324 • Number of events 35 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Asthenia	6.5% 21/324 • Number of events 30 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.0% 13/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Chest pain	0.62% 2/324 • Number of events 2 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Influenza like illness	3.1% 10/324 • Number of events 28 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.2% 7/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Oedema peripheral	7.4% 24/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	7.4% 24/324 • Number of events 31 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Peripheral swelling	4.3% 14/324 • Number of events 15 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	8.0% 26/324 • Number of events 30 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
General disorders Pyrexia	10.8% 35/324 • Number of events 44 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	11.4% 37/324 • Number of events 50 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Immune system disorders Hypogammaglobulinaemia	3.7% 12/324 • Number of events 13 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 13 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Bronchitis	5.9% 19/324 • Number of events 22 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	8.0% 26/324 • Number of events 34 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations COVID-19	37.3% 121/324 • Number of events 163 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	25.9% 84/324 • Number of events 105 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations COVID-19 pneumonia	4.0% 13/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.6% 15/324 • Number of events 20 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Cellulitis	3.7% 12/324 • Number of events 15 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.0% 13/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Conjunctivitis	2.2% 7/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.6% 15/324 • Number of events 20 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Ear infection	3.1% 10/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	1.2% 4/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Gastroenteritis	3.1% 10/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	1.9% 6/324 • Number of events 6 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Herpes zoster	3.4% 11/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Lower respiratory tract infection	3.7% 12/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Nasopharyngitis	6.2% 20/324 • Number of events 26 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.9% 16/324 • Number of events 23 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Oral herpes	1.2% 4/324 • Number of events 9 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.0% 13/324 • Number of events 17 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Paronychia	1.5% 5/324 • Number of events 6 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pharyngitis	1.9% 6/324 • Number of events 8 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Pneumonia	10.2% 33/324 • Number of events 47 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	11.4% 37/324 • Number of events 57 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Respiratory tract infection	4.9% 16/324 • Number of events 20 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.2% 7/324 • Number of events 8 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Rhinitis	3.1% 10/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Sinusitis	6.2% 20/324 • Number of events 26 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.9% 16/324 • Number of events 19 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Skin infection	2.2% 7/324 • Number of events 8 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.0% 13/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Upper respiratory tract infection	29.3% 95/324 • Number of events 155 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	19.8% 64/324 • Number of events 105 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Infections and infestations Urinary tract infection	10.8% 35/324 • Number of events 68 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	9.6% 31/324 • Number of events 58 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Contusion	15.1% 49/324 • Number of events 62 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	11.7% 38/324 • Number of events 44 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Fall	4.9% 16/324 • Number of events 19 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	7.1% 23/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Injury, poisoning and procedural complications Skin laceration	3.7% 12/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	1.9% 6/324 • Number of events 6 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Alanine aminotransferase increased	3.7% 12/324 • Number of events 20 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	6.2% 20/324 • Number of events 29 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Aspartate aminotransferase increased	2.2% 7/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.9% 16/324 • Number of events 23 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Blood alkaline phosphatase increased	1.5% 5/324 • Number of events 8 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 15 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Blood bilirubin increased	2.5% 8/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 20 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Blood creatinine increased	5.6% 18/324 • Number of events 36 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 21 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Blood pressure increased	1.9% 6/324 • Number of events 19 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Gamma-glutamyltransferase increased	3.1% 10/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Neutrophil count decreased	8.0% 26/324 • Number of events 75 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	7.4% 24/324 • Number of events 69 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Platelet count decreased	3.4% 11/324 • Number of events 40 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	6.2% 20/324 • Number of events 47 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Investigations Weight decreased	6.8% 22/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.3% 14/324 • Number of events 20 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Decreased appetite	3.7% 12/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	6.8% 22/324 • Number of events 23 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Gout	1.2% 4/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hyperglycaemia	4.0% 13/324 • Number of events 21 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.5% 8/324 • Number of events 8 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hyperuricaemia	4.9% 16/324 • Number of events 37 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	6.8% 22/324 • Number of events 37 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hypokalaemia	7.4% 24/324 • Number of events 39 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	7.4% 24/324 • Number of events 39 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Hyponatraemia	3.1% 10/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.5% 8/324 • Number of events 13 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Metabolism and nutrition disorders Type 2 diabetes mellitus	4.3% 14/324 • Number of events 15 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Arthralgia	16.7% 54/324 • Number of events 69 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	19.4% 63/324 • Number of events 85 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Back pain	8.0% 26/324 • Number of events 26 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	8.0% 26/324 • Number of events 30 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Joint swelling	3.1% 10/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Muscle spasms	4.0% 13/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	13.0% 42/324 • Number of events 51 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Myalgia	3.4% 11/324 • Number of events 13 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.3% 14/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Osteoarthritis	1.2% 4/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Musculoskeletal and connective tissue disorders Pain in extremity	8.0% 26/324 • Number of events 30 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	8.0% 26/324 • Number of events 30 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	3.4% 11/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	5.2% 17/324 • Number of events 40 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	4.3% 14/324 • Number of events 21 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.6% 15/324 • Number of events 23 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Dizziness	9.9% 32/324 • Number of events 39 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	8.0% 26/324 • Number of events 28 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Headache	9.0% 29/324 • Number of events 36 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	10.8% 35/324 • Number of events 46 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Paraesthesia	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Nervous system disorders Syncope	3.4% 11/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.5% 8/324 • Number of events 9 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Psychiatric disorders Anxiety	3.4% 11/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.3% 14/324 • Number of events 22 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Psychiatric disorders Insomnia	7.7% 25/324 • Number of events 27 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	8.0% 26/324 • Number of events 28 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Renal and urinary disorders Haematuria	5.6% 18/324 • Number of events 23 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.0% 13/324 • Number of events 20 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Cough	14.2% 46/324 • Number of events 59 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	13.3% 43/324 • Number of events 55 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Dyspnoea	4.9% 16/324 • Number of events 19 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.0% 13/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Epistaxis	8.3% 27/324 • Number of events 46 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	7.4% 24/324 • Number of events 45 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	3.7% 12/324 • Number of events 14 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.1% 10/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Respiratory, thoracic and mediastinal disorders Productive cough	5.2% 17/324 • Number of events 18 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Actinic keratosis	2.5% 8/324 • Number of events 16 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 15 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Ecchymosis	1.5% 5/324 • Number of events 5 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Erythema	3.4% 11/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.8% 9/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Petechiae	9.9% 32/324 • Number of events 41 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	5.9% 19/324 • Number of events 19 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Pruritus	7.4% 24/324 • Number of events 32 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.8% 9/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Rash	11.7% 38/324 • Number of events 69 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	13.6% 44/324 • Number of events 58 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Rash maculo-papular	3.7% 12/324 • Number of events 15 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	2.2% 7/324 • Number of events 10 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Skin and subcutaneous tissue disorders Skin haemorrhage	2.5% 8/324 • Number of events 12 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.7% 12/324 • Number of events 13 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Haematoma	5.2% 17/324 • Number of events 23 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	4.3% 14/324 • Number of events 17 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Hypertension	25.3% 82/324 • Number of events 154 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	22.8% 74/324 • Number of events 155 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.
Vascular disorders Hypotension	0.93% 3/324 • Number of events 3 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.	3.4% 11/324 • Number of events 11 • All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm. All-cause mortality is reported for all randomized participants. Adverse events are all reported for all participants who received any dose of study drug.

Additional Information

Study Director

BeiGene

Phone: +1-877-828-5568

Email: clinicaltrials@beigene.com

Results disclosure agreements

• Principal investigator is a sponsor employee BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.
• Publication restrictions are in place

Restriction type: OTHER